Jayasree Iyer – CEO, Access to Medicine Foundation
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Address: Vijzelmolenlaan 9, 3447 GX, Woerden,Netherlands
Tel: +31 348574222
Web: http://www.b-ms.nl/
The headquarters of Bristol-Myers Squibb (B-MS) Netherlands several divisions are located in Woerden.
B-MS is originally an American company and has offices worldwide. B-MS has operated for over 40 years In the Netherlands and is a leader in innovative medicines and health products.
For more information about B-MS International, visit: http://www.bms.com/
Squibb settled in 1967 in The Hague. Bristol-Myers since 1971 in the Netherlands. In 1989 both companies merged and Woerden was chosen as a location for BMS.
B-MS has 35,000 employees worldwide, of which 110 work in the Netherlands.
Global B-MS had 2008 sales of $ 20.6 billion.
In 2008, $ 3.6 billion invested in the development of new drugs (17.4% of revenue in 2007 was 17.0%).
B-MS is represented in the associations Nefarma, Netherlands Association of Innovative Drugs and AmCham, American Chamber of Commerce. Both are active in the field of advocacy for the innovative pharmaceutical industry. Topics include: authorization and reimbursement of new drugs, the funding of medicines and promote a favorable climate for innovation in the Netherlands. For more information about the industry, visit: http://www.nefarma.nl or http://www.amchampc.org
The mission of our company is focused on the life of man to the length and quality of life by developing innovative medicines and health products. The research of B-MS is focused on disease areas where there is a medical need, such as cancer, HIV / AIDS, diabetes, rheumatism, hepatitis, schizophrenia, heart disease and obesity.
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
